Baseline renal insufficiency and risk of death among HIV-infected adults on antiretroviral therapy in Lusaka, Zambia

AIDS

Volumn 22, Issue 14, 2008, Pages 1821-1827

  Mulenga, Lloyd B ^a   Kruse, Gina ^a   Lakhi, Shabir ^b   Cantrell, Ronald A ^a,c   Reid, Stewart E ^a,c   Zulu, Isaac ^d,e   Stringer, Elizabeth M ^a,c   Krishnasami, Zipporah ^c   Mwinga, Alwyn ^d   Saag, Michael S ^c   Stringer, Jeffrey Sa ^a,c   Chi, Benjamin H ^a,c,f  

^a CENTRE FOR INFECTIOUS DISEASE RESEARCH IN ZAMBIA   (Zambia)

^b UNIVERSITY TEACHING HOSPITAL   (Zambia)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e UNIVERSITY OF ZAMBIA   (Zambia)

^f Plot 1275 ^*  (Zambia)

Author keywords

Antiretroviral therapy; HIV; Mortality; Renal disease; Sub Saharan Africa; Survival; Zambia

Indexed keywords

ANTIRETROVIRUS AGENT; CREATININE;

ADOLESCENT; ADULT; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIET; DISEASE SEVERITY; DOSE RESPONSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; ZAMBIA;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; CREATININE; DEVELOPING COUNTRIES; DISEASE PROGRESSION; FEMALE; GLOMERULAR FILTRATION RATE; HIV INFECTIONS; HIV-1; HUMANS; MALE; ODDS RATIO; PREVALENCE; PROPORTIONAL HAZARDS MODELS; RENAL INSUFFICIENCY; RISK; ZAMBIA;

EID: 66349085980     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328307a051     Document Type: Article

References (39)

1. Szczech LA. Renal diseases associated with human immunodeficiency virus infection: epidemiology, clinical course, and management. Clin Infect Dis 2001; 33:115-119.
2. Ross MJ, Fan C, Ross MD, Chu TH, Shi Y, Kaufman L, et al. HIV-1 infection initiates an inflammatory cascade in human renal tubular epithelial cells. J Acquir Immune Defic Syndr 2006; 42:1-11.
3. Weiner NJ, GoodmanJW, Kimmel PL. The HIV-associated renal diseases: current insight into pathogenesis and treatment. Kidney Int 2003; 63:1618-1631.
4. Franceschini N, Napravnik S, Finn WF, Szczech LA, Eron JJ Jr. Immunosuppression, hepatitis C infection, and acute renal failure in HIV-infected patients. J Acquir Immune Defic Syndr 2006; 42:368-372.
5. Glassock RJ, Cohen AH, Danovitch G, Parsa KP. Human immunodeficiency virus (HIV) infection and the kidney. Ann Intern Med 1990; 112:35-49.
6. Isnard Bagnis C, Deray G, Baumelou A, Le Quintrec M, Vanherweghem JL. Herbs and the kidney. Am J Kidney Dis 2004; 44:1-11.
7. Szczech LA, Hoover DR, Feldman JG, Cohen MH, Gange SJ, Gooze L, et al. Association between renal disease and outcomes among HIV-infected women receiving or not receiving anti-retroviral therapy. Clin Infect Dis 2004; 39:1199-1206.
8. Gardner LI, Holmberg SD, Williamson JM, Szczech LA, Carpenter CC, Rompalo AM, et al. Development of proteinuria or elevated serum creatinine and mortality in HIV-infected women. J Acquir Immune Defic Syndr 2003; 32:203-209.
9. Wyatt CM, Arons RR, Klotman PE, Klotman ME. Acute renal failure in hospitalized patients with HIV: risk factors and impact on in-hospital mortality. AIDS 2006; 20:561-565.
10. Ole-Nguyaine S, Crump JA, Kibiki GS, Kiang K, Taylor J, Schimana W, et al. HIV-associated morbidity, mortality and diagnostic testing opportunities among inpatients at a referral hospital in northern Tanzania. Ann Trop Med Parasitol 2004; 98:171-179.
11. UN AIDS. Report on the global AIDS epidemic. Geneva: World Health Organization; 2006.
12. Naicker S. End-stage renal disease in sub-Saharan and South Africa. Kidney Int Suppl 2003; S119-S122.
13. StringerJS, Zulu I, LevyJ, Stringer EM, Mwango A, Chi BH, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 2006; 296:782-793.
14. Bolton-Moore C, Mubiana-Mbewe M, Cantrell RA, Chintu N, Stringer EM, Chi BH, et al. Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary healthcare facilities in Zambia. JAMA 2007; 298:1888-1899.
15. Zambian Ministry of Health. Antiretroviral therapy for chronic HIV infection in adults and adolescents: new ART protocols, May 2007. Lusaka, Zambia: Printech Press; 2007.
16. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.
17. Sanusi AA, Akinsola A, Ajayi AA. Creatinine clearance estimation from serum creatinine values: evaluation and comparison of five prediction formulae in Nigerian patients. AfrJ Med Med Sci 2000; 29:7-11.
18. Peters P, Moore D, MerminJ, BrooksJ, Downing R, Were W, et al. Renal function improves among Ugandans on NNRTI-based HAART: 24-month follow-up from the home-based AIDS care program in rural Uganda. In: 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA; 2007, [abstract 791].
19. Muloma E, Owino-Ong'or W, Sidle J, Gupta S, Aubrey R, Kiprunto K, et al. Renal disease in an antiretroviral naive HIV-infected population in western Kenya. In: Third IAS Conference on HIV Pathogenesis and Treatment. Rio de Janiero, Brazil; 2005, [abstract MoPe1 1.6C23].
20. Andia I, Pepper L, Matheison P. Prevalence of renal disease in patients attending the HIV/AIDS clinic at Mbarara University Teaching Hospital. In: Third IAS Conference on HIV Pathogenesis and Treatment. Rio de Janiero, Brazil; 2005, [abstract TuPe15.3C02].
21. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39:S1 -S266.
22. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130:461-470.
23. Couchoud C, Pozet N, Labeeuw M, Pouteil-Noble C. Screening early renal failure: cut-off values for serum creatinine as an indicator of renal impairment. Kidney Int 1999; 55:1878-1884.
24. McNutt LA, Wu C, Xue X, HafnerJP. Estimating the relative risk in cohort studies and clinical trials of common outcomes. Am J Epidemiol 2003; 157:940-943.
25. Zou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004; 159:702-706.
26. Lin DY, Wei LJ, Ying Z. Checking the Cox model with cumulative sums of martingale-based residuals. Biometrika 1993; 80:557-572.
27. Erikstrup C, Kallestrup P, Zinyama R, Gomo E, Mudenge B, Gerstoft J, et al. Predictors of mortality in a cohort of HIV-1-infected adults in rural Africa. J Acquir Immune Defic Syndr 2007; 44:478-483.
28. Zachariah R, Fitzgerald M, Massaquoi M, Pasulani O, Arnould L, Makombe S, et al. Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi. AIDS 2006; 20:2355-2360.
29. van derSandeMA, Schim van der Loeff MF, Aveika AA, Sabally S, Togun T, Sarge-Njie R, et al. Body mass index at time of HIV diagnosis: a strong and independent predictor of survival. J Acquir Immune Defic Syndr 2004; 37:1288-1294.
30. Szczech LA, Gupta SK, Habash R, Guasch A, Kalayjian R, Appel R, et al. The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. Kidney Int 2004; 66:1145-1152.
31. Han TM, Naicker S, Ramdial PK, Assounga AG. A cross-sectional study of HI V-seropositive patients with varying degrees of proteinuria in South Africa. Kidney Int 2006; 69:2243-2250.
32. Smith MC, Austen JL, Carey JT, Emancipator SN, Herbener T, Gripshover B, et al. Prednisone improves renal function and proteinuria in human immunodeficiency virus-associated ne-phropathy. Am J Med 1996; 101:41-48.
33. Eustace JA, Nuermberger E, Choi M, Scheel PJ Jr, Moore R, Briggs WA. Cohort study of the treatment of severe HIV-associated nephropathy with corticosteroids. Kidney Int 2000; 58:1253-1260.
34. Burns GC, Paul SK, Toth IR, Sivak SL. Effect of angiotensin-converting enzyme inhibition in HIV-associated nephropathy. ) Am Soc Nephrol 1997; 8:1140-1146.
35. Wei A, Burns GC, Williams BA, Mohammed NB, Visintainer P, Sivak SL. Long-term renal survival in HIV-associated nephropathy with angiotensin-converting enzyme inhibition. Kidney Int 2003; 64:1462-1471.
36. GallantJE, Staszewski S, PozniakAL, DeJesus E, Suleiman JM, Miller MD, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191-201.
37. Mauss S, Berger F, Schmutz G. Antiretroviral therapy with tenofovir is associated with mild renal dysfunction. AIDS 2005; 19:93-95.
38. Julg BD, BognerJR, Crispin A, Goebel FD. Progression of renal impairment under therapy with tenofovir. AIDS 2005; 19:1332-1333.
39. Peyriere H, Reynes J, Rouanet I, Daniel N, de Boever CM, Mauboussin JM, et al. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr 2004; 35:269-273.